Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥124.8bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥180.1bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥88.5bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥6.1bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥3.6bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥6.2bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥9.3bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.7bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥5.0bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥3.6bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥1.2bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.9bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.9bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥2.3bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥1.9bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥137.3bnat 2024-09-30Cons.Assets
Total assets¥117.8bnat 2024-03-31Cons.Assets
Total assets¥107.4bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥79.3bnat 2024-09-30Cons.Liabilities
Total liabilities¥64.9bnat 2024-03-31Cons.Liabilities
Net assets / equity¥58.0bnat 2024-09-30Cons.Net assets
Net assets / equity¥52.8bnat 2024-03-31Cons.Net assets
Net assets / equity¥50.3bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥21.8bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥27.3bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥21.5bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥26.9bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥17.3bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥18.6bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥477m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥13.5bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥6.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow¥265m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥13.2bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥9.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.2bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥8.0bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥2.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥32.432024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥131.112023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥50.82023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio39.3%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio44.8%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio46.8%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥686m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥686m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥1.8bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue2024-04-01 → 2024-09-30¥84.1bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue external2024-04-01 → 2024-09-30¥84.1bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥64m
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentsegment profit2024-04-01 → 2024-09-30¥4.2bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue2024-04-01 → 2024-09-30¥7.4bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue external2024-04-01 → 2024-09-30¥6.8bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥622m
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentsegment profit2024-04-01 → 2024-09-30¥928m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥33.9bn
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥33.9bn
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥2.7bn
—segment totalrevenue2024-04-01 → 2024-09-30¥125.5bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥124.8bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥686m
—segment totalsegment profit2024-04-01 → 2024-09-30¥7.9bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥237m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥237m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.8bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue2023-04-01 → 2023-09-30¥81.0bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue external2023-04-01 → 2023-09-30¥81.0bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥63m
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentsegment profit2023-04-01 → 2023-09-30¥4.7bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥6.7bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥173m
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥801m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥897m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥897m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥142m
—segment totalrevenue2023-04-01 → 2023-09-30¥88.8bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥88.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥237m
—segment totalsegment profit2023-04-01 → 2023-09-30¥5.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 543
ItemContextValueUnit
Interest expenses ope cfPrior1YTDDuration51000000JPY
Interest expenses ope cfCurrentYTDDuration97000000JPY
Decrease increase in inventories ope cfPrior1YTDDuration-460000000JPY
Decrease increase in inventories ope cfCurrentYTDDuration-1075000000JPY
Decrease increase in notes and accounts receivable trade ope cfPrior1YTDDuration455000000JPY
Decrease increase in notes and accounts receivable trade ope cfCurrentYTDDuration-2026000000JPY
Increase decrease in notes and accounts payable trade ope cfPrior1YTDDuration892000000JPY
Increase decrease in notes and accounts payable trade ope cfCurrentYTDDuration-2357000000JPY
Other net ope cfPrior1YTDDuration1062000000JPY
Other net ope cfCurrentYTDDuration-1033000000JPY
Subtotal ope cfPrior1YTDDuration8299000000JPY
Subtotal ope cfCurrentYTDDuration1528000000JPY
Interest and dividends income received ope cf inv cfPrior1YTDDuration3000000JPY
Interest and dividends income received ope cf inv cfCurrentYTDDuration5000000JPY
Interest expenses paid ope cf fin cfPrior1YTDDuration-51000000JPY
Interest expenses paid ope cf fin cfCurrentYTDDuration-97000000JPY
Income taxes paid ope cfPrior1YTDDuration-1860000000JPY
Income taxes paid ope cfCurrentYTDDuration-958000000JPY
Net cash provided by used in operating activitiesPrior1YTDDuration6391000000JPY
Net cash provided by used in operating activitiesCurrentYTDDuration477000000JPY
Payments into time deposits inv cfPrior1YTDDuration-1000000JPY
Payments into time deposits inv cfCurrentYTDDuration-5000000JPY
Proceeds from withdrawal of time deposits inv cfPrior1YTDDuration-JPY
Proceeds from withdrawal of time deposits inv cfCurrentYTDDuration26000000JPY
Purchase of property plant and equipment inv cfPrior1YTDDuration-1239000000JPY
Purchase of property plant and equipment inv cfCurrentYTDDuration-997000000JPY
Proceeds from sales of property plant and equipment inv cfPrior1YTDDuration55000000JPY
Proceeds from sales of property plant and equipment inv cfCurrentYTDDuration53000000JPY
Purchase of intangible assets inv cfPrior1YTDDuration-115000000JPY
Purchase of intangible assets inv cfCurrentYTDDuration-316000000JPY
Collection of loans receivable inv cfPrior1YTDDuration4000000JPY
Collection of loans receivable inv cfCurrentYTDDuration8000000JPY
Payments for lease and guarantee deposits inv cfPrior1YTDDuration-72000000JPY
Payments for lease and guarantee deposits inv cfCurrentYTDDuration-59000000JPY
Proceeds from collection of lease and guarantee deposits inv cfPrior1YTDDuration34000000JPY
Proceeds from collection of lease and guarantee deposits inv cfCurrentYTDDuration88000000JPY
Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cfPrior1YTDDuration-759000000JPY
Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cfCurrentYTDDuration-2368000000JPY
Proceeds from purchase of investments in subsidiaries resulting in change in scope of consolidation inv cfPrior1YTDDuration-JPY
Proceeds from purchase of investments in subsidiaries resulting in change in scope of consolidation inv cfCurrentYTDDuration3972000000JPY
Purchase of stocks of subsidiaries and affiliates inv cfPrior1YTDDuration-7500000000JPY
Purchase of stocks of subsidiaries and affiliates inv cfCurrentYTDDuration-JPY
Payments for transfer of business2 inv cfPrior1YTDDuration-253000000JPY
Payments for transfer of business2 inv cfCurrentYTDDuration-JPY
Proceeds from transfer of business inv cfPrior1YTDDuration-JPY
Proceeds from transfer of business inv cfCurrentYTDDuration6000000JPY
Other net inv cfPrior1YTDDuration-59000000JPY
Other net inv cfCurrentYTDDuration-142000000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration-9905000000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration265000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass